- Home
- LSAK vs ALT Comparison
LSAK vs ALT Comparison
Compare LSAK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- ALT
- Stock Information
- Founded
- LSAK 1997
- ALT 1997
- Country
- LSAK South Africa
- ALT United States
- Employees
- LSAK N/A
- ALT N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- LSAK Finance
- ALT Health Care
- Exchange
- LSAK Nasdaq
- ALT Nasdaq
- Market Cap
- LSAK 344.5M
- ALT 292.0M
- IPO Year
- LSAK N/A
- ALT N/A
- Fundamental
- Price
- LSAK $4.74
- ALT $3.83
- Analyst Decision
- LSAK
- ALT Strong Buy
- Analyst Count
- LSAK 0
- ALT 6
- Target Price
- LSAK N/A
- ALT $17.40
- AVG Volume (30 Days)
- LSAK 18.6K
- ALT 3.0M
- Earning Date
- LSAK 09-10-2025
- ALT 08-12-2025
- Dividend Yield
- LSAK N/A
- ALT N/A
- EPS Growth
- LSAK N/A
- ALT N/A
- EPS
- LSAK N/A
- ALT N/A
- Revenue
- LSAK $574,080,000.00
- ALT $20,000.00
- Revenue This Year
- LSAK $1.06
- ALT N/A
- Revenue Next Year
- LSAK $13.32
- ALT $761,880.20
- P/E Ratio
- LSAK N/A
- ALT N/A
- Revenue Growth
- LSAK 4.13
- ALT N/A
- 52 Week Low
- LSAK $3.39
- ALT $2.90
- 52 Week High
- LSAK $5.60
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- LSAK 51.59
- ALT 51.79
- Support Level
- LSAK $4.60
- ALT $3.35
- Resistance Level
- LSAK $4.76
- ALT $3.66
- Average True Range (ATR)
- LSAK 0.11
- ALT 0.19
- MACD
- LSAK -0.01
- ALT 0.07
- Stochastic Oscillator
- LSAK 36.73
- ALT 86.18
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.